A PYMNTS Company

US: Johnson & Johnson announces $4.15B diagnostics sale

 |  January 16, 2014

Pharmaceutical and self-care giant Johnson & Johnson announced with asset management firm The Carlyle Group a sale of J&J’s diagnostics unit in a deal made for $4.15 billion, say reports.

Johnson & Johnson will sell its Ortho-Clinical Diagnostics business to Carlyle, which deemed the purchase a reflection of the predicted growth of the diagnostics market and its evolving importance to clinical healthcare practices.

The parties said they expect to close the deal mid-2014, though the acquisition remains subject to regulatory approval.

The OCD business provides early screening and diagnostic services, among others.

Full Content: Genetic Engineering & Biotechnoloty News

Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.